Two myelin oligodendrocyte glycoprotein ) monoclonal antibodies (mAbs) were produced from an A.SW mouse with progressive experimental autoimmune encephalomyelitis. Polyreactivity/specificity of the mAbs was demonstrated by ELISA. Functionality and a potential role in pathogenesis of systemic autoimmunity were demonstrated in vitro in a lymphocytotoxicity assay and in vivo upon injection into naïve mice. Injection of MOG mAb producing hybridomas into naïve mice resulted in immunoglobulin deposition in kidneys and liver. This model will be useful in determining whether transitional forms between CNS (organ)-specific and systemic autoimmune diseases exist, and whether progressive multiple sclerosis has features of a systemic autoimmune disease.
Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) which encompasses a diverse spectrum of clinical disease (Willenborg and Staykova, 2003) . The clinical course of MS can be categorized into four forms based on the presence or absence of relapses and remission and/or progression of neurological deficits: relapsing-remitting (RR), primary-progressive (PP), secondary progressive (SP) and progressive-relapsing (PR) (Lublin and Reingold, 1996) . RR-MS is characterized by alternating disease relapses and periods of full recovery or sequelae. PP-MS is defined by its continuous disease progression from the onset. Patients with SP-MS initially present with RR disease which is then followed by disease progression. In contrast, PR-MS starts out progressive and is followed by definite acute relapses with or without full remission. Mechanisms of transition and differences between the various forms of MS are not well understood, due in part to the bias towards research on RR disease based on the availability of animal models (Thompson et al., 1997) . PP-MS is clinically, epidemiologically, pathologically, and immunologically different from the other forms of MS (Pender et al., 2003; Sadatipour et al., 1998) , which begs the question whether PP-MS and RR-MS are two distinct diseases (Larsen et al., 1985; McDonald, 1994; Olerup et al., 1989) .
Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig) superfamily (Gardinier et al., 1992) , is encoded within the major histocompatibility complex (MHC) (Pham-Dinh et al., 1993) and can be detected on the surface of oligodendrocytes and myelin in the CNS (Linington et al., 1984) . T and B cells reactive against MOG have been identified in demyelinating lesions and cerebrospinal fluid (CSF) of patients with MS (Genain et al., 1999; Reindl et al., 1999; Sun et al., 1991; Xiao et al., 1991) , and MOG-specific antibody has been found deposited within lesions (Genain et al., 1999 
